Septerna, Inc. (SEPN)
| Market Cap | 469.64M |
| Revenue (ttm) | 977,000 |
| Net Income (ttm) | -79.11M |
| Shares Out | 44.56M |
| EPS (ttm) | -3.89 |
| PE Ratio | n/a |
| Forward PE | 17.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,966 |
| Open | 10.16 |
| Previous Close | 10.17 |
| Day's Range | 10.08 - 10.57 |
| 52-Week Range | 4.17 - 28.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 27.00 (+156.17%) |
| Earnings Date | May 15, 2025 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM f... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $27.0, which is an increase of 156.17% from the latest price.
News
Septerna to Present at Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ann...
Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR pla...
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock t...
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday.
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that cou...
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Collaboration combines Novo Nordisk's scientific leadership in obesity and cardiometabolic diseases with Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop mu...
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for M...
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Septerna, Inc. ("Se...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SE...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SE...
Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SE...
Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SE...
Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SE...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Septerna to Present at TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today an...
Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDA...